c-Met: a well-suited target for payload delivery by antibodies – a pipeline review

STUTTGART, Germany I August 15, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-c-Met immunotherapeutics in R&D: Pipeline of c-Met-Targeted Immunotherapies.

This competitive intelligence report about c-Met-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research and development targeting c-Met. This report will be prepared on demand within one working day upon order placement. The report lists c-Met-targeted active R&D programs by R&D phase in a tabular format and describes in brief the profile of c-Met-targeted immunotherapies by drug modality. The report will be provided in pdf format and sent by e-mail to the customer.

As an example of this category of on demand reports please see our free sample report of “Pipeline of 5T4-Targeted Immunotherapies”.

The c-MET signalling pathway consists of the mesenchymal epithelial transition factor (c-MET) transmembrane receptor tyrosine kinase receptor (RTK) and its ligand hepatocyte growth factor (HGF) or scatter factor (SF). Binding of HGF/SF to c-MET activates downstream signalling pathways such as Rho, focal adhesion kinase (FAK) and PI3K. These pathways regulate cancer cell growth, survival angiogenesis, invasion and metastasis. Thus, prevention of c-MET dependent neoplastic processes may provide a means for managing invasive tumors of high metastatic potential. c-Met is a well-characterized oncogene that is associated with poor prognosis in many solid tumor types.

In fact, c-MET/HGF has evolved as an attractive target for the pharmaceutical industry. Several c-Met RTK inhibitors have made it to the market to treat non-small cell lung cancer with specific MET mutations—Novartis’ Tabrecta (capmatinib), Merk KGaA’s Tepmetko (tepotinib) and AstraZeneca and HutchMed’s Orpathys (savolitinib) in China—validating c-Met as a viable target. While responses to c-Met RTK inhibitors have been observed in clinical trials, activity appears to be limited to those with MET gene amplifications or exon 14-skipping mutations, representing only small subsets of patients with tumors driven by signaling through the c-Met pathway, thereby necessitating selection of patients with MET amplification and/or c-Met activation most likely to respond.

As a cell surface receptor, c-Met is highly expressed in solid tumors, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), and, thus, may be well suited as a binding target for delivery of payloads.

The report “Pipeline of c-Met-Targeted Immunotherapies” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/pipeline-of-c-met-targeted-immunotherapies/

About La Merie Publishing

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.

La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, customized reports about target evaluation, pipeline analysis, technology assessments, drug and competitor profiles, partnering and business deal terms and any other competitive intelligence elaboration of interest.

SOURCE: La Merie Publishing